News|Videos|March 20, 2024

Challenges in Trial Treatment and Access for Women with Chronic Illnesses

In this Applied Clinical Trials video interview, Marie Teil, Global Head of UCB’s Women of Childbearing Age Program, discusses the specific challenges women with chronic illnesses face when it comes to participating in clinical trials.

Beyond the data gap for pregnancy, what other specific challenges do women with chronic illnesses face when it comes to accessing appropriate treatment and participating in clinical trials?

So indeed, women with chronic illnesses, face specific challenges when it comes to accessing appropriate treatment. And actually, it starts with having relevant information and data from clinical trials. So first of all, to be clear, women's health includes reproductive health, but also covers general conditions that may affect women differently, or disproportionately, like higher prevalence, higher disease burden for women. And I'm just going to give you a couple of examples.

In rheumatic diseases for example, research show that women can experience longer delays in diagnosis, greater pain, anxiety, stress, and can as a result be less active. The same way in psoriatic diseases, which is a disease that affects both skin and joints, women experience a greater feeling of stigmatization are more likely to suffer from stress loneliness than men. And maybe another example we can think about is one of three women will suffer from fragility fracture due to osteoporosis during her lifetime. And despite all that, health challenges for women are still consistently overlooked with studies that ignore the contribution of gender differences in significant condition. So as a result, treatment guidelines, at least at the moment do not recognize gender as a reason to consider different approaches to their care. And policies and frameworks need to ensure they reflect an equality-based approach to the care of women.

Actually, health systems that take account, gender differences in their public health strategies are more likely to be successful and have a greater societal impact. We know that now. Right? So, most women with chronic illnesses are often diagnosed during the height of their careers and their reproductive years. And then they will face specific challenges. One of them could be the desire to continue working, but sometimes building a family as well when managing their disease. And it is critical to improve the standard of care for these women. So, they don't have to make tradeoffs between controlling their disease or planning their family and daily living the life they choose.


Related to this article

What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why the full burden of developmental and epileptic encephalopathies extends far beyond clinical symptoms—and why endpoints must reflect what families are actually hoping for.
What It Actually Means to Embed the Patient Voice in Trial Design
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, explains why genuine patient partnership begins before the protocol is written—and what it looks like when patients and caregivers tell you a trial was designed with them in mind.
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
In this video interview, Sylviane de Viron of CluePoints and Abigail Dirks of Tufts CSDD explain how ICH E6(R3) and new empirical evidence of RBQM's net financial impact give sponsors the tools they need to build the multi-functional buy-in required for successful adoption—and why RBQM only delivers full value when it replaces, not supplements, traditional monitoring.